Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 3;35(6):727-732.
doi: 10.1515/jpem-2021-0200. Print 2022 Jun 27.

Considering metformin as a second-line treatment for children and adolescents with prediabetes

Chelsea M Hosey  1 , Kelsee Halpin  2   3 , Yun Yan  2
Affiliations
Review

Considering metformin as a second-line treatment for children and adolescents with prediabetes

Chelsea M Hosey et al. J Pediatr Endocrinol Metab. .

Abstract

Overweight and obesity affect approximately 1/3 of children in the United States and are risk factors for prediabetes and type 2 diabetes. Progression from prediabetes to diabetes carries substantial long-term health burdens, culminating in decreased life-expectancy. Earlier development of type 2 diabetes is associated with poorer prognoses, and children lose glycemic control more rapidly than adults. Metformin is approved by the USFDA for the treatment of type 2 diabetes in children, has limited toxicity, and may help prevent the development of type 2 diabetes. The more rapid disease progression in children and the safety of metformin suggests that initiation of metformin treatment to children with prediabetes who have not effectively responded to lifestyle changes may help prevent short- and long-term health damage resulting from prediabetic and diabetic dysglycemia.

Keywords: metformin; pediatrics; prediabetes.

PubMed Disclaimer

References

    1. Andes, LJ, Cheng, YJ, Rolka, DB, Gregg, EW, Imperatore, G. Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016. JAMA Pediatr 2019;174:e194498.
    1. Divers, J, Mayer-Davis, EJ, Lawrence, JM, Isom, SP, Dabelea, D, Dolan, L, et al.. Trends in incidence of type 1 and type 2 diabetes among youths — selected counties and Indian reservations, United States, 2002–2015. MMWR Morb Mortal Wkly Rep 2020;69:161–5, https://doi.org/10.15585/mmwr.mm6906a3.
    1. Copeland, KC, Zeitler, P, Geffner, M, Guandalini, C, Higgins, J, Hirst, K, et al.. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011;96:159–67, https://doi.org/10.1210/jc.2010-1642.
    1. Hamman, RF, Bell, RA, Dabelea, D, D’Agostino, RBJr., Dolan, L, Imperatore, G, et al.. The SEARCH for Diabetes in Youth study: rationale, findings, and future directions. Diabetes Care 2014;37:3336–44, https://doi.org/10.2337/dc14-0574.
    1. Shi, Q, Zhang, X, Jiang, F, Zhang, X, Hu, N, Bimu, C, et al.. Clinical characteristics and Risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care 2020;43:1382–91, https://doi.org/10.2337/dc20-0598.

LinkOut - more resources